Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 3, 2010, Pages 494-498

  Bamba, Shigeki ^a   Tsujikawa, Tomoyuki ^a   Inatomi, Osamu ^a   Nakahara, Tamio ^a   Koizumi, Yusuke ^a   Saitoh, Yasuharu ^a   Sasaki, Masaya ^a   Fujiyama, Yoshihide ^a   Andoh, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Azathioprine; Colectomy; Cyclosporine A; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PREDNISOLONE;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; COLON RESECTION; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; COLECTOMY FREE SURVIVAL RATE; CONTINUOUS INFUSION; DRUG WITHDRAWAL; HYPOMAGNESEMIA; INCIDENCE; MENTAL DISEASE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 77649201371     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06119.x     Document Type: Article

References (9)

1. Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003 52 : 998 1002.
2. Gornet JM, Couve S, Hassani Z et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment. Pharmacol. Ther. 2003 18 : 175 181.
3. Sandborn W. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm. Bowel. Dis. 1995 1 : 48 63.
4. Actis GC, Ottobrelli A, Pera A et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J. Clin. Gastroenterol. 1993 17 : 10 13.
5. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994 330 : 1841 1845.
6. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm. Bowel. Dis. 1999 5 : 1 10.
7. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am. J. Gastroenterol. 1992 87 : 971 976.
8. Selgrade MK, Daniels MJ, Dean JH. Correlation between chemical suppression of natural killer cell activity in mice and susceptibility to cytomegalovirus: rationale for applying murine cytomegalovirus as a host resistance model and for interpreting immunotoxicity testing in terms of risk of disease. J. Toxicol. Environ. Health 1992 37 : 123 137.
9. Inoue S, Howgate EM, Rowland-Yeo K et al. Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 2006 36 : 499.